CHOICE OF THE OPTIMAL METHOD OF TREATMENT OF LOCALLY ADVANCED RECTAL CANCER.
Keywords:
locally advanced rectal cancer, chemoradiation therapy, neoadjuvant chemotherapy, consolidation chemotherapy, induction chemotherapy, SANDWICH therapy, pathomorphism. capecitabine; ox aliplatin.Abstract
Rectal cancer is one of the most common forms of malignant neoplasms both in the world oncological practice and in Uzbekistan. About 600,000 new cases of this disease are diagnosed annually in the world. Over the past few decades, there has been a steady increase in the incidence of rectal cancer. The data on the relative incidence of this nosology are comparable among Russian and foreign authors according to Siegel R., Miller K., rectal cancer, including anal canal cancer, accounts for about 50% of all colon tumors. In recent years, there has been a tendency towards an increase in the incidence of rectal cancer worldwide, so its share in the structure of oncological morbidity in men is 5.3% and in women 4.4%. Locally advanced rectal cancer is a tumor of limited mobility or immobile with involvement or destruction of its own fascia, without obvious signs of distant metastasis in patients who, due to its spread beyond the organ, cannot undergo radical surgery without a high risk of local relapse in the near future after surgery. One of the urgent tasks of modern oncoproctology is to improve the long-term results of treatment of patients with locally advanced rectal cancer (LARC).
Downloads
References
Andre T., Boni C., Mounedji-Boudiaf [et al.] Oxaliplatin, fluorouracil and leucovorinas adjuvant treatment for colon cancer // N. Engl. J. Med. 2004. V. 350. P. 2343-2351.
Arnold D. & Schmoll H.-J. (Neo-) adjuvant treatment in colorectal cancer // Ann. Oncol. 2005. V. 15 (suppl. 2). P. 133-140.
Bosset JF, Magnin V., Maingon P. [et al.] Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial // Int. J. Radiat . Oncol. Biol. Phys. 2000. No. 46 (2). P. 323-327.
Cassidy J., Twelves C., Nowacki M. [et al.] Improved safety of capecitabine versus bolus 5-fluorouracil/leucovorin adjuvant therapy for colon cancer (the X-ACT phase III study) // Gastrointestinal Cancer Symposium. 2004. abstr. 219.
Cervantes A., Chirivella I., Rodriguez-Braun E. [et al.] A multimodality approach to localized rectal cancer // Annals of oncology. 2006. V. 18 (suppl. 10). P 129-134.
Chouaib S. et al., 2012; Chen T. et al., 2009; Dayanc BE, et al., 2008. DOI: 10.1116/S1470-2045(17)30786-4.
Crane CH, Skibber JM, Birnbaum EH [et al.] The addition of continuous infusion of 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer // Int. J. Radiat. Oncol. Biol. Phys. 2003. No. 57 (1). P. 84-89.
De Gramont A., Boni C., Navarro M. [et al.] Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results on the MOSAIC trial, including survival, with a median follow-up of six years // ASCO. 2007. V. 25 (suppl. 18). abstr. 4007.
Erlandsson J., Holm T., Pettersson D. et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomized, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017;18(3):336–46. DOI: 10.1016/S1470-2045(17)30086-4.
Evans J., Bhoday J., Sizer B. et al. Results of a prospective randomized control 6 vs 12 trial: is greater tumor downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy. Ann Oncol 2016;27(Suppl 6):vi149 (abstr. 4520). DOI: 10.1093/annonc/mdw370.01.
Glynne-Jones R., Sebag-Montefiore D., Maugahn TS [et al.] A phase I dose escalation study of continuous oral capecitabine with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer // Ann. Oncol. 2006. V. 17. P. 50-56.
Kalofonos HP, Pentheroudakis G., Rigatos S. [et al.] A randomized phase III trial of adjuvant radio-chemotherapy comparing irinotecan (CPT-11), 5FU and leucovorin to 5FU and leucovorin in patients with rectal cancer // Annals Oncol. 2006. V. 17. (suppl. 9): Ab. 3320 (P. 116).
Kim SW et al., 2018; Fradkin S.Z. et al., 1982; Janssen HL et al., 2005; Lee-Kong SA et al., 2012.
Lefevre JH, Mineur L, Kotti S et al. Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 2016;34(31):3773–80. DOI: 10.1200/JCO.2016.67.6049.
MA Skibber., Rich TA, Ajani JA [et al.] Preoperative infusional chemoradiation therapy for stage T3 rectal cancer // Int. J. Radiat. Oncol. Biol. Phys. 1995. No. 32 (4). P. 1025-1029.
MC Roh.. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 // J. Clin. Oncol. 2011. V. 29. (I 18S, Part I). R. 221S (abstr. 3503).
MD Becker., Sauer R., Hohenberger W. [et al.] Preoperative chemo/radiotherapy as compared with post-operative chemo/radiotherapy for locally advanced rectal cancer. // N. Engl. J. Med. 2004. V. 351. P. 1731-1740.
MD Smalley SR, Benedetti JK, Williamson SK [et al.] Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in post-operative adjuvant rectal cancer: GI INT 0144 // J. Clin. Oncol. 2006. No. 24 (22). R. 3542-3547.
ME Anscher Tyler SD, Chari RS [et al.] Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum // Ann. Surg. 1995. No. 221 (6). P. 778-787.
Minsky BD, Grann SG, Cohen AM [et al.] Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer // Dis. Colon. Rectum. 1997. No. 40 (5). P. 515-522.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.
